Place of cryosurgery in the treatment of malignant liver tumors

被引:228
作者
Adam, R
Akpinar, E
Johann, M
Kunstlinger, F
Majno, P
Bismuth, H
机构
[1] Hepatobiliary Surg. Liver T.U., Hôpital Paul Brousse, Université Paris Sud, Villejuif
关键词
D O I
10.1097/00000658-199701000-00005
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective The authors evaluate the results of cryosurgery in malignant liver tumors. Summary Background Data The outcome of primary or secondary achieved. Encouraging results of cryosurgery have been reported in unresectable liver tumors, but this treatment needs further evaluation of its efficacy in homogeneous groups of patients. Methods From 63 patients with malignant liver tumors with various histology treated by cryosurgery in a 2.5-year period, the authors evaluated the results of 34 patients with nonresectable hepatocellular carcinoma (9 patients) or nonresectable metastases from colorectal cancer (25 patients). Cryosurgery was used either as a single treatment (4 hepatocellular carcinomas, 5 metastases) or in association with liver resection (5 hepatocellular carcinomas, 20 metastases). Systemic chemotherapy was used routinely before surgery and after surgery. Results There was no intraoperative mortality. Mortality within 2 months was 3% and was unrelated to the procedure. Postoperative morbidity consisted of one sterile fluid collection and one biliary fistula (8%). Ata mean follow-up of 16 months, (range, 2-27) local recurrence rate was 0% for hepatocellular carcinoma and 44% for metastases. Cumulative survival at 24 months was 63% and 52%, respectively, with 6 patients (67%) and 5 patients (20%) currently disease free. In the group of patients with metastases, survival was related to the size of the treated tumor (p=0.06) and the absence of residual disease (p=0.03). Conclusions Cryosurgery is safe and increases the number of patients with unresectable liver malignancies in whom surgery can aim at eradicating the tumor. Local recurrence is observed more frequently for metastases than for hepatocellular carcinoma. The benefit in survival is related to the complete treatment of the tumoral disease.
引用
收藏
页码:39 / 49
页数:11
相关论文
共 37 条
  • [1] ADAM R, 1992, BR J SURG S, V79, pS79
  • [2] RESECTION OF LIVER METASTASES - WHEN IS IT WORTHWHILE
    ADSON, MA
    [J]. WORLD JOURNAL OF SURGERY, 1987, 11 (04) : 511 - 520
  • [3] OPTIONS FOR ELECTIVE TREATMENT OF PORTAL-HYPERTENSION IN CIRRHOTIC-PATIENTS IN THE TRANSPLANTATION ERA
    BISMUTH, H
    ADAM, R
    MATHUR, S
    SHERLOCK, D
    [J]. AMERICAN JOURNAL OF SURGERY, 1990, 160 (01) : 105 - 110
  • [4] PRIMARY-TREATMENT OF HEPATOCELLULAR-CARCINOMA BY ARTERIAL CHEMOEMBOLIZATION
    BISMUTH, H
    MORINO, M
    SHERLOCK, D
    CASTAING, D
    MIGLIETTA, C
    CAUQUIL, P
    ROCHE, A
    [J]. AMERICAN JOURNAL OF SURGERY, 1992, 163 (04) : 387 - 394
  • [5] CADY B, 1992, ARCH SURG-CHICAGO, V127, P561
  • [6] CRYOTHERAPY FOR LIVER METASTASES - A NEW APPROACH
    CHARNLEY, RM
    DORAN, J
    MORRIS, DL
    [J]. BRITISH JOURNAL OF SURGERY, 1989, 76 (10) : 1040 - 1041
  • [7] FALKSON G, 1988, CANCER RES, V48, P7314
  • [8] CURRENT TREATMENT MODALITIES FOR HEPATOCELLULAR-CARCINOMA
    FARMER, DG
    ROSOVE, MH
    SHAKED, A
    BUSUTTIL, RW
    [J]. ANNALS OF SURGERY, 1994, 219 (03) : 236 - 247
  • [9] HUGHES KS, 1988, SURGERY, V103, P278
  • [10] LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO